Student or educator? Sign up with your school email and get 6 months of Pro free.

The DOI matches its Crossref record; 169 of the 169 references it cites were found in a registry or an index.

Atherosclerosis

Abstract

Atherosclerosis, the formation of fibrofatty lesions in the artery wall, causes much morbidity and mortality worldwide, including most myocardial infarctions and many strokes, as well as disabling peripheral artery disease. Development of atherosclerotic lesions probably requires low-density lipoprotein, a particle that carries cholesterol through the blood. Other risk factors for atherosclerosis and its thrombotic complications include hypertension, cigarette smoking and diabetes mellitus. Increasing evidence also points to a role of the immune system, as emerging risk factors include inflammation and clonal haematopoiesis. Studies of the cell and molecular biology of atherogenesis have provided considerable insight into the mechanisms that link all these risk factors to atheroma development and the clinical manifestations of this disease. An array of diagnostic techniques, both invasive (such as selective coronary arteriography) and noninvasive (such as blood biomarkers, stress testing, CT and nuclear scanning), permit assessment of cardiovascular disease risk and targeting of therapies. An expanding armamentarium of therapies that can modify risk factors and confer clinical benefit is available; however, we face considerable challenge in providing equitable access to these treatments and in maximizing adherence. Yet, the clinical application of the fruits of research has advanced preventive strategies, enhanced clinical outcomes in affected individuals, and improved their quality of life. Rapidly accelerating knowledge and continued research promise to provide further progress in combating this common chronic disease.

Overview

Integrity signals

Registry

Crossref · 10.1038/s41572-019-0106-z

Cites

169 of 169 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

Show all 169 references

Research works printed but not linked: 14

  1. WHO. Cardiovascular disease: Global Hearts Initiative. (World Health Organization, Geneva, 2018).
  2. Hochholzer, W. & Giugliano, R. P. Lipid lowering goals: back to nature? Ther. Adv. Cardiovasc. Dis. 4, 185–191 (2010).
  3. Geng, Y.-J. & Libby, P. Evidence for apoptosis in advanced human atheroma. Co-localization with interleukin-1 beta-converting enzyme. Am. J. Pathol. 147, 251–266 (1995).
  4. Yurdagul, A., Doran, A. C., Cai, B., Fredman, G. & Tabas, I. A. Mechanisms and consequences of defective efferocytosis in atherosclerosis. Front. Cardiovasc. Med. 8, 4–86 (2018).
  5. Libby, P. & Pasterkamp, G. Requiem for the ‘vulnerable plaque’. Eur. Heart J. 36, 2984–2987 (2015).
  6. Rumberger, J. A. Coronary artery disease: a continuum, not a threshold. Mayo Clin. Proc. 92, 323–326 (2017).
  7. Wilson, J. M. & Jungner, Y. G. Principles and practice of mass screening for disease [article in Spanish]. Bol. Oficina Sanit. Panam. 65, 281–393 (1968).
  8. Ridker P. M., Libby P. and Buring J. E. in Braunwald's Heart Disease: A Textbook of Cardiovascular Medicine, 10th Edition (ed. Braunwald, E.) 891–933 (Saunders, 2014).
  9. Department of Health and Human Services. Food and Drug Aministration. AbbVie Inc. et al. Withdrawal of approval of indications related to the coadministration with statins in applications for niacin extended-release tablets and fenofibric acid delayed-release capsules. Fed. Regist. 81, 22612–22613 (2016).
  10. Cholesterol Treatment Trialists’ (CTT) Collaboration. Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170 000 participants in 26 randomised trials. Lancet 376, 1670–1681 (2010). · DOI · Paper page
  11. Stone, N. J. et al. 2013 ACC/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. Circulation 129, S1–S45 (2014). · DOI · Paper page
  12. Sabatine, M. S. et al. Evolocumab and clinical outcomes in patients with cardiovascular disease. N. Engl. J. Med. 376, 1713–1722 (2017). · DOI · Paper page
  13. Landmesser, U. et al. European Society of Cardiology/European Atherosclerosis Society Task Force consensus statement on proprotein convertase subtilisin/kexin type 9 inhibitors: practical guidance for use in patients at very high cardiovascular risk. Eur. Heart J. 38, 2245–2255 (2017). A masterful review of an important innovation in anti-atherosclerotic therapy with an emphasis on its practical application.
  14. Thomas L. The Lives of a Cell. New York: Penguin Books; 1974: 31–36.

Cited by

See all 3,211

Metadata

Authors
Libby, P., Buring, J. E., Badimon, L., Hansson, G. K., Deanfield, J., Bittencourt, M. S., Tokgözoğlu, L., & Lewis, E. F.
Affiliations
  • Brigham and Women's Hospital (US)
  • Karolinska University Hospital (SE)
  • University College London (GB)
  • Universidade de São Paulo (BR)
  • Hacettepe University (TR)
Corresponding author
Libby, Peter
Venue
Nature Reviews Disease Primers
Published
2019-08-16
Volume
5
Issue
1
Pages
56-56
ISSN
2056-676X (ISSN-L)
OpenAlex
W4211134725
Cited by
3,211
References
169
Citations by year
2026: 452 · 2025: 550 · 2024: 587 · 2023: 532 · 2022: 502 · 2021: 380 · 2020: 179 · 2019: 17
FWCI
23.50
Type
journal article
Language
en
Open access
closed
Licence
Locations
  • Nature Reviews Disease Primers (publishedVersion)
  • PubMed (publishedVersion)
Funders
National Heart, Lung, and Blood Institute (R01HL080472)
Topics
  • Life Sciences › Immunology and Microbiology › Immunology › Atherosclerosis and Cardiovascular Diseases
  • Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Lipoproteins and Cardiovascular Health
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Biochemistry › Cholesterol and Lipid Metabolism
Keywords
atherosclerosis, atherogenesis, low-density lipoprotein, cholesterol, hypertension, smoking, diabetes mellitus, inflammation, clonal hematopoiesis, atherosclerotic plaque, thrombotic complications, cardiovascular risk assessment, blood biomarkers, cardiovascular imaging, lipid-lowering therapy, medication adherence, cardiovascular disease prevention
MeSH terms
Drug Therapy, Humans, Hyperlipidemias, Mass Screening, Risk Factors, Atherosclerosis

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Atherosclerosis. https://app.cochat.ai/papers/10.1038/s41572-019-0106-z
The paper
Libby, P., Buring, J. E., Badimon, L., Hansson, G. K., Deanfield, J., Bittencourt, M. S., Tokgözoğlu, L., & Lewis, E. F. (2019). Atherosclerosis. Nature Reviews Disease Primers. https://doi.org/10.1038/s41572-019-0106-z

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.